Bioxytran Inc
OTC:BIXT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Song Da No 9 JSC
VN:SD9
|
VN |
Bioxytran Inc
Inventory
Bioxytran Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioxytran Inc
OTC:BIXT
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Inventory
$5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Inventory
$1.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Inventory
$6.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Inventory
$1.7B
|
CAGR 3-Years
54%
|
CAGR 5-Years
43%
|
CAGR 10-Years
40%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Inventory
$2.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
Bioxytran Inc
Glance View
BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. The company is headquartered in Needham, Massachusetts. The company went IPO on 2010-01-05. The Company’s lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application that includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiaries, provides lead pharmaceutical drug candidate, ProLectin-Rx. ProLectin-Rx is a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, which is a type of galectin.
